Corrects typo in headline

Overview

• US cancer drug maker's Q1 net product revenue reached $5.8 mln in first full commercial quarter

• Company reported robust new patient starts and early launch momentum for KOMZIFTI

• Collaboration revenue declined yr/yr, net loss widened due to higher R&D and SG&A expenses

Outlook

• Company expects multiple clinical data readouts for ziftomenib in 2026 across AML settings

• Kura expects current cash and collaboration payments to fund ziftomenib program through 2028 topline results

• Company aims for sustained quarter-over-quarter growth in KOMZIFTI revenue and adoption

Result Drivers

• EARLY LAUNCH MOMENTUM - Co cited robust new patient starts, repeat use, switching from other therapies, and initial combination adoption as drivers of KOMZIFTI revenue

• PAYER ACCESS - Broad and rapid payer access with over 93% coverage supported commercial uptake

• COMMERCIAL INVESTMENT - Higher R&D and SG&A expenses driven by advancement of ziftomenib combination trials and commercialization investments

Company press release: ID:nGNXbPd0tf

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.83
Q1 Net Income		-$73.33 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Kura Oncology Inc is $28.00, about 194.4% above its May 11 closing price of $9.51

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.